ClinicalTrials.gg
RecruitingNCT05407857TaiPEIUpdated Oct 28, 2022

Taiwan Geriatric Study for Dementia Risk Prevention and Cognitive Enhancement by Multi-modal Intervention

An interventional study of multi-modal non-pharmacological intervention in Dementia, sponsored by Taipei Medical University Shuang Ho Hospital. Recruiting at 1 site in Taiwan. Open to participants aged 60 Years to 90 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-10-28.

Sponsored by Taipei Medical University Shuang Ho Hospital · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Jul 2022; still recruiting 4 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
380
Allocation
Randomized
Ages
60 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 105 studies in Dementia with a site in Taiwan — 23 open to participants now, 28 under way, 1 of them phase 3. Dementia · Taiwan.

Planned enrollment
9th of 84
380 · median 100
Started
2022
with 11 others
No phase
66 of 105
12 open now
Primary completion
2026-12
later than 12 of 27 live
Registered
54th of 105
by date
Lead sponsor
6 of 105
Taipei Medical University Shuang Ho Hospital

Among the 105 studies in Dementia with a site in Taiwan, this one is the 9th largest by planned enrollment of the 84 interventional ones that give a count, is one of 12 that started in 2022, is one of 66 with no phase, reaches primary completion later than 12 of the 27 other live ones, and was the 54th registered.

Dementia

2,377 studies on the registry are indexed under Dementia; 572 are open to participants now.

Browse Dementia studies →

Open to participants now

23 of the 105 studies in Dementia with a site in Taiwan are open now. Recruiting first, the newest first:

17 more — sign in →

All 23 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 382 Dementia studies recruiting now, 242 (63%) set no upper age limit and 25 (7%) stop at 75 or younger; 15 take children under 18; 163 take healthy volunteers.

This study: 60 Years to 90 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 105 studies in Dementia with a site in Taiwan, or all of them as a file.
02

Study summary

A 3-arm randomized controlled trial of multi-modal non-pharmacological Intervention for preventing the risk of dementia in Taiwanese geriatric people

Read the detailed description

This project proposes an intervention program for dementia prevention based on the Taiwanese model. The investigator(s) will screen the elderly who are not yet demented but are at high risk of dementia and will randomly allocate them into three groups (on site intervention group, remote intervention group, and control group) for a two-year multi-modal non-pharmacological intervention. All intervention groups will be actively involved in management with nutrition, exercise and cognitive programs. The on-site intervention group requires subjects to participate in prescribed place according to the protocol. The remote intervention group is designed for reducing the chances of person-to-person contact response to the current coronavirus disease 2019 (COVID-19) pandemic and development of digital internet. It uses innovative technology combining wearable devices with inertial measurement units, blue-tooth equipment, apps, feedback technology and artificial intelligence based remote comprehensive training programs. During the study period, each group will be regularly monitored the changes of cardiovascular risk factors, physical performance and cognitive function. The results of multimodal intervention mainly from Taipei and New Taipei City will establish the Taiwan FINGER model (TaiPEI) and will have the information of the conditions and feasibility achieved in Taiwan and implementation suggestions in the face of the epidemic. It can be subsequently applied to the brain/body health care institution and to the prevention of dementia and cardiovascular disease of elderly.

03

Conditions studied

  • Dementia

Browse trials for

04

Who can participate

Ages eligible
60 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. People over 60 without dementia
  2. Agree to join the study and sign the consent form
  3. The Modified Rankin Scale (MRS) scores between 0-1 points
  4. Education level: elementary or higher education (6 years) or can read and write Chinese
  5. Very early dementia screening scale (AD-8) \< 2, or more than 2 points but without dementia diagnoses after refer to a neurologist.
  6. Cardiovascular Risk Factors, Aging, and Incidence of Dementia (CAIDE) Risk Score: above 8; diagnosed with mild cognitive impairment (MCI) or subjective cognitive decline (SCD) in the past six months.

Exclusion criteria

Exclusion Criteria:

  1. Have been diagnosed with any kind of dementia
  2. Suspected dementia patients or others who are not suitable to participate in the research assessed by a doctor at the first visit
  3. Diseases affecting the safety of various interventional activities (such as remaining life less than two years, symptomatic heart/cerebrovascular disease within 6 months, vascular reperfusion or reconstruction-related surgery within one year, etc., malignant tumor within one year)
  4. Severe blindness, hearing or communication impairment, or other difficulty in cooperating or completing assessments and interventions (especially exercise) in the study
  5. Severe mental illnesses, including major depression disorder, or major neuromusculoskeletal disorders that are not suitable to join the study.
  6. Drug or alcohol abuse in the last year
  7. Overlapping with other interventional trials at the same time which may affect the evaluation results.
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
380 participants (estimated)

Study arms

  • Experimental
    On-site

    The on-site multi-modal intervention will be actively involved in management with nutrition, exercise and cognitive programs. The on-site intervention group requires subjects to participate in prescribed place according to the protocol.

    Behavioral: multi-modal non-pharmacological intervention

  • Active comparator
    Remote

    The remote intervention group is designed for reducing the chances of person-to-person contact response to the current COVID-19 pandemic and development of digital internet. It uses innovative technology combining wearable devices with inertial measurement units, blue-tooth equipment, apps, feedback technology and artificial intelligence based remote comprehensive training programs.

    Behavioral: multi-modal non-pharmacological intervention

  • Placebo comparator
    Control

    The control group will also receive the same health evaluation and education as all intervention groups.

    Behavioral: multi-modal non-pharmacological intervention

Interventions

  • Behavioralmulti-modal non-pharmacological intervention

    multi-modal non-pharmacological intervention including the management with nutrition, exercise and cognitive programs

06

What researchers measure

Primary outcomes

  1. Change in cognition including individual cognitive domains, unit on a scale

    A composite z-score will be obtained from the neuropsychological tests evaluating multiple cognitive domains, including memory, language, process speed, visuospatial, and executive function.

    Time frame: Before intervention (Baseline); During intervention (every six month); follow-up (6 months after intervention ends)

Secondary outcomes

  1. Change in physical assessment, unit on a scale

    Senior Fitness Test (SFT) measures six functional areas of physical function (strength, endurance, balance, agility, and flexibility)

    Time frame: Before intervention (Baseline); During intervention (every six month); follow-up (6 months after intervention ends)

  2. Change in physical assessment, unit on a scale

    Short Physical Performance Battery (SPPB), score range: 0-12; higher scores mean a better outcome.

    Time frame: Before intervention (Baseline); During intervention (every six month); follow-up (6 months after intervention ends)

  3. Change in physical assessment, unit on a scale

    International Physical Activity Questionnaire (IPAQ), a 27-item self-reported measure of physical activity

    Time frame: Before intervention (Baseline); During intervention (every six month); follow-up (6 months after intervention ends)

  4. Change in physical functioning - Hand-grip strength, kg

    Measured using a hand-grip dynamometer

    Time frame: Before intervention (Baseline); During intervention (every six month); follow-up (6 months after intervention ends)

  5. Change of the questionnaire regarding the nutrition, unit on a scale

    Mini Nutritional Assessment-Short Form (MNA-SF), a screening scale used to assess current nutritional status. score range: 0-14, higher scores mean a better outcome.

    Time frame: Before intervention (Baseline); During intervention (every six month); follow-up (6 months after intervention ends)

  6. Change of the questionnaire regarding the nutrition, unit on a scale

    food frequency questionnaire (FFQ), a finite list of foods and beverages with response categories to indicate usual frequency of consumption over the time period

    Time frame: Before intervention (Baseline); During intervention (every six month); follow-up (6 months after intervention ends)

  7. Change of nutrition intake, unit on a scale

    3-day dietary record: a self-reported account of all foods and beverages consumed within recent three days

    Time frame: Before intervention (Baseline); During intervention (every six month); follow-up (6 months after intervention ends)

  8. Change in functioning level, unit on a scale

    Activities of Daily Living Questionnaire (ADLQ)

    Time frame: Before intervention (Baseline); During intervention (every six month); follow-up (6 months after intervention ends)

  9. Change in functioning level, unit on a scale

    The Brief University of California San Diego (UCSD) Performance-Based Skills Assessment (UPSA-Brief) -Traditional Chinese Version: two subdomains (Finances, Communication) with a total score ranging from 0 to 100.

    Time frame: Before intervention (Baseline); During intervention (every six month); follow-up (6 months after intervention ends)

  10. Change in functioning level, unit on a scale

    Florida Cognitive Activities Scale (FCAS): a 25-item scale used to assess cognitive activities in the elderly with two subscales (Higher Cognitive Abilities and Frequent Cognitive Abilities)

    Time frame: Before intervention (Baseline); During intervention (every six month); follow-up (6 months after intervention ends)

  11. Change in functioning level, unit on a scale

    EuroQol five-dimensional (EQ-5D): an instrument for measuring quality of life regarding the five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression.

    Time frame: Before intervention (Baseline); During intervention (every six month); follow-up (6 months after intervention ends)

  12. Change in functioning level, unit on a scale

    Activities of Daily Living Questionnaire (ADLQ), The Brief University of California San Diego (UCSD) Performance-Based Skills Assessment(Traditional Chinese Version)(UPSA-Brief), Florida Cognitive Activities Scale(FCAS), EuroQol five-dimensional (EQ-5D)

    Time frame: Before intervention (Baseline); During intervention (every six month); follow-up (6 months after intervention ends)

  13. Change in depressive symptoms, unit on a scale.

    Geriatric Depression Scale-Short Form (GDS-S), score range: 0-15; higher scores mean a worse outcome.

    Time frame: Before intervention (Baseline); During intervention (every six month); follow-up (6 months after intervention ends)

  14. Change in sleep symptoms, unit on a scale.

    Epworth sleepiness scale (ESS)

    Time frame: Before intervention (Baseline); During intervention (every six month); follow-up (6 months after intervention ends)

  15. Change in sleep symptoms, unit on a scale.

    Pittsburgh Sleep Quality Index (PSQI)

    Time frame: Before intervention (Baseline); During intervention (every six month); follow-up (6 months after intervention ends)

  16. Change in blood tests - fasting plasma glucose, mmol/L.

    Measured from fasting blood sample

    Time frame: Before intervention (Baseline); During intervention (every six month); follow-up (6 months after intervention ends)

  17. Change in blood tests - triglycerides, mmol/L.

    Measured from fasting blood sample

    Time frame: Before intervention (Baseline); During intervention (every six month); follow-up (6 months after intervention ends)

  18. Change in blood tests - Albumin, prealbumin, g/dL.

    Measured from fasting blood sample

    Time frame: Before intervention (Baseline); During intervention (every six month); follow-up (6 months after intervention ends)

  19. Change of Plasma amyloid beta, pg/mL

    Assessed by ultra-sensitive, immunomagnetic reduction assay (MagQu, LLC, Surprise, AZ),

    Time frame: Before intervention (Baseline); During intervention (6th month and 24th month)

  20. Change of Plasma tau, pg/mL

    Assessed by ultra-sensitive, immunomagnetic reduction assay (MagQu, LLC, Surprise, AZ),

    Time frame: Before intervention (Baseline); During intervention (6th month and 24th month)

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2022 (actual). Primary completion is estimated for Dec 2026, 53 months after the start.

Of 862 non-industry interventional studies with no phase under Dementia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 53 months is above that.

Counting every sponsor, half of 908 studies reached it within 25 months; a quarter within 11 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 31, 2022
First posted
Jun 7, 2022
StartActual
Jul 1, 2022
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Oct 28, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 28, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05407857
Responsible party
Yi-Chun Kuan (Physician, Department of Neurology, Principal Investigator, Associate Professor, Taipei Medical University Shuang Ho Hospital) — Principal investigator
First posted
Jun 7, 2022
Start date
Jul 1, 2022
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Oct 28, 2022

Study contacts

Yi-Chun Kuan, MD
Contact
yckuang2@gmail.com
+886-222490088 ext. 8112
Yi-Chun Kuan, MD
principal investigator · Taipei Medical University Shuang Ho Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion